arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Vor Biopharma Inc.

VOR

$23.65 ▼ -0.07 (-0.30%) at close

7 Visible periods

18 Metrics

Absolute Benchmarks

Price Chart

Health

Poor

Neutral Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, Vor Biopharma Inc. shows solid but mixed fundamentals, with Return on Invested Capital holding up well. Watch FCF / Net Income against typical quality thresholds. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $233.5M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC 178.7% ↗

FCF / Share $-14.55 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-695.98M

↓ -495.3% —

FCF / Share Free cash flow per share

$-14.55

↑ +50.0% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

Return on Invested CapitalReturn on Invested Capital of 178.7% is excellent on an absolute basis (target > 10%)

warning

Bearish Risks

FCF / Net IncomeFCF / Net Income of 0.21x is weak on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	-107.2% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	2.8% Caution ↓ Caution Declining Year-over-year change in earnings per share Optimal: > 10%	24.9% Good Good Year-over-year change in earnings per share Optimal: > 10%	-11.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-495.3% Weak ↓ Weak Declining Year-over-year change in net income	0.8% Caution ↑ Caution Improving Year-over-year change in net income	-28.0% Weak ↑ Weak Improving Year-over-year change in net income	-33.7% Weak Weak Year-over-year change in net income	-59.0% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	50.0% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	3.6% Caution ↓ Caution Declining Year-over-year change in free cash flow	36.3% Excellent Excellent Year-over-year change in free cash flow	-8.3% Weak Weak Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
FCF / Net Income (x)	0.21x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.02x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	1.06x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	178.7% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-99.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-66.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-29.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-25.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	58.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-80.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-84.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-63.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-31.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-28.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-57.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	—	-120.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-906%)	-78.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-621%)	-36.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-345%)	-31.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-312%)	73.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+389%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Net Debt (USD)	$-396.49M	$-81.95M	$-31.36M	$-57.71M	$-119.80M	$-48.54M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-70.50	$-34.03	$-35.00	$-46.60	$-42.00	—	—
Free Cash Flow per Share (USD)	$-14.55	$-29.08	$-30.17	$-47.33	$-43.69	—	—
Book Value per Share (USD)	$-4.24	$15.49	$44.40	$75.95	$116.35	$-2.34K	—
Tangible Book Value per Share (USD)	$-4.24	$15.49	$44.40	$75.95	$116.35	$-2.34K	—
Basic Weighted Avg Shares (shares)	9.87M	3.44M	3.36M	1.98M	1.67M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$432.93M	$77.89M	$125.23M	$223.83M	$204.25M	$38.90M	—
Total Equity (USD)	$-164.31M	$96.66M	$150.72M	$250.61M	$216.26M	$-59.06M	$-17.43M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	$2.89M	$3.53M	$3.49M	$2.52M	$1.43M	$605.00K	—
Net Income, GAAP (USD)	$-695.98M	$-116.91M	$-117.86M	$-92.09M	$-68.90M	$-43.34M	—
Operating Cash Flow (USD)	$-142.71M	$-99.66M	$-100.29M	$-85.14M	$-69.14M	$-36.29M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Vor Biopharma Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare VOR with peers